Wellbeing Digital Sciences Inc. (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company announced that its wholly-owned subsidiary KGK Science Inc. completed an open-label study, where Gefion Canada  GT4 technology was used to successfully deliver cannabidiol (CBD) and tetrahydrocannabinol (THC) to healthy volunteers in the form of a topical cream applied to the skin, according to a press release.

Wellbeing Digital Sciences Inc. focuses on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research.

Gefion GT4 Technology

GT4 Technology uses novel penetrating agents to transport CBD and THC through the skin and directly into the blood.

"Transdermal delivery of topically-applied …

Full story available on Benzinga.com